CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR IDE study evaluated the long-term clinical and hemodynamic outcomes of the intra-annular self-expanding Navitor valve.

This was a prospective, multicenter study conducted at 26 centers across Europe, Australia, and the United States. A total of 260 patients with symptomatic severe aortic stenosis who were considered at high or extreme surgical risk were included.

The analysis presented corresponds to the CE-mark cohort (n=120), with clinical and echocardiographic follow-up up to 5 years.

The safety analysis showed favorable long-term outcomes. All-cause mortality was 37.1% at 5 years (consistent with the high surgical risk profile of the included population). The cumulative incidence of stroke was 12.2%.

Regarding the hemodynamic profile during follow-up, long-term stability was observed. At five years the following values were reported:

  • Mean aortic gradient: 6.9 mmHg

  • Effective orifice area (EOA): approximately 2.0 cm²

  • Low incidence of major paravalvular leak during follow-up (likely related to the active sealing cuff system).

Device durability was favorable throughout follow-up. At five years, bioprosthetic valve deterioration (BVD) was observed in 5.9% of patients, structural valve deterioration (SVD) in 0%, and valve reintervention in 0%.

Read also: CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty.

The authors noted that the 35 mm valve size was introduced later and was not included in the presented analysis.

The results of the NAVITOR IDE study demonstrate sustained hemodynamic performance and favorable five-year durability of the intra-annular self-expanding Navitor valve in patients with severe aortic stenosis at high surgical risk.

Presented by Bassem Chehab in the Late Breaking Clinical Trials session, CRT 2026, Washington, USA.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...

Can Coronary CT Angiography Replace Invasive Coronary Angiography in Pre-TAVI Coronary Assessment?

Coronary artery disease coexists in approximately half of patients undergoing transcatheter aortic valve implantation, making coronary assessment prior to the procedure essential. Invasive coronary...

Valve-in-Valve in Small Surgical Aortic Bioprostheses: Balloon-Expandable or Self-Expanding? Three-Year Results from the LYTEN Trial

Dysfunction of small surgical aortic bioprostheses represents a challenging scenario for transcatheter aortic valve replacement in the valve-in-valve setting, due to the higher incidence...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...